Latest Insider Transactions at Iovance Biotherapeutics, Inc. (IOVA)
This section provides a real-time view of insider transactions for Iovance Biotherapeutics, Inc. (IOVA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of IOVANCE BIOTHERAPEUTICS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of IOVANCE BIOTHERAPEUTICS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 23
2022
|
Iain D. Dukes Director |
BUY
Open market or private purchase
|
Direct |
10,000
+31.25%
|
$60,000
$6.1 P/Share
|
|
Aug 23
2022
|
Merrill A Mcpeak Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+39.94%
|
$200,000
$5.65 P/Share
|
|
Jun 14
2022
|
Igor Bilinsky Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,346
-49.58%
|
$65,422
$7.73 P/Share
|
|
Jun 14
2022
|
Igor Bilinsky Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,850
+50.0%
|
-
|
|
Jun 14
2022
|
Jean Marc Bellemin Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,346
-49.58%
|
$65,422
$7.73 P/Share
|
|
Jun 14
2022
|
Jean Marc Bellemin Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,850
+50.0%
|
-
|
|
Jun 14
2022
|
Finckenstein Friedrich Graf Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,809
-34.58%
|
$47,663
$7.73 P/Share
|
|
Jun 14
2022
|
Finckenstein Friedrich Graf Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,690
+50.0%
|
-
|
|
Jun 01
2022
|
Frederick G Vogt Interim CEO & General Counsel |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$6,000
$6.44 P/Share
|
|
Jun 01
2022
|
Wayne P. Rothbaum Director |
BUY
Open market or private purchase
|
Indirect |
500,000
+5.84%
|
$3,000,000
$6.43 P/Share
|
|
May 31
2022
|
Wayne P. Rothbaum Director |
BUY
Open market or private purchase
|
Indirect |
500,000
+6.2%
|
$3,000,000
$6.77 P/Share
|
|
May 31
2022
|
Michael Weiser Director |
BUY
Open market or private purchase
|
Direct |
10,000
+4.27%
|
$60,000
$6.8 P/Share
|
|
May 31
2022
|
Ryan D Maynard Director |
BUY
Open market or private purchase
|
Direct |
7,500
+50.0%
|
$45,000
$6.75 P/Share
|
|
May 31
2022
|
Merrill A Mcpeak Director |
BUY
Open market or private purchase
|
Indirect |
10,000
+4.37%
|
$60,000
$6.8 P/Share
|
|
May 31
2022
|
Merrill A Mcpeak Director |
BUY
Open market or private purchase
|
Direct |
10,000
+33.17%
|
$60,000
$6.84 P/Share
|